Xenetic Biosciences (XBIO) Other Non Operating Income (2014 - 2026)
Xenetic Biosciences' (XBIO) quarterly Other Non Operating Income came in at -$21.0 in Q1 2026, down 126.92% YoY from $78.0 in Q1 2025, and down 113.21% on a QoQ basis from $159.0 in Q4 2025.
Xenetic Biosciences (XBIO) Other Non Operating Income (2014 - 2026) Analysis & Trends
Xenetic Biosciences (XBIO) has 13 years of Other Non Operating Income data on file, last reported at -$21.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 126.92% year-over-year to -$21.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5626.0 (up 199.01% YoY) and the FY2025 annual result came in at $5725.0, up 200.3% from the prior year.
- Other Non Operating Income fell to -$21.0 in Q1 2026, from $159.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $21122.0 in Q2 2023 to a low of -$7243.0 in Q4 2024.
- A 5-year average of $1398.8 and a median of $159.0 in 2025 frame the typical range for Other Non Operating Income.
- Annual changes were most pronounced in 2024 — Other Non Operating Income slumped 1892.82% — and 2025, when it jumped 7133.33%.
- Tracing XBIO's Other Non Operating Income over 5 years: stood at $986.0 in 2022, then tumbled by 59.03% to $404.0 in 2023, then tumbled by 1892.82% to -$7243.0 in 2024, then surged by 102.2% to $159.0 in 2025, then tumbled by 113.21% to -$21.0 in 2026.
- The last three Other Non Operating Income figures came in at -$21.0 (Q1 2026), $159.0 (Q4 2025), and $4011.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Xenetic Biosciences | 8.01 Mn | 1.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -72.00 |
| Mar 31, 2026 | -21.00 |
| Dec 31, 2025 | 159.00 |
| Sep 30, 2025 | 4,011.00 |
| Jun 30, 2025 | 1,477.00 |
| Mar 31, 2025 | 78.00 |
| Dec 31, 2024 | -7,243.00 |
| Sep 30, 2024 | 1,504.00 |
| Jun 30, 2024 | -21.00 |
| Mar 31, 2024 | 52.00 |
| Dec 31, 2023 | 404.00 |
| Sep 30, 2023 | -666.00 |
| Jun 30, 2023 | 21,122.00 |
| Mar 31, 2023 | 4,520.00 |
| Dec 31, 2022 | 986.00 |
| Sep 30, 2022 | -1,706.00 |
| Jun 30, 2022 | -1,076.00 |
| Mar 31, 2022 | 199.00 |
| Dec 31, 2021 | 2,903.00 |
| Sep 30, 2021 | -2,906.00 |